ArticleTherapeutic advances in endocrinology and metabolism2026
Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists have transitioned from clinical tools for diabetes to a global cultural phenomenon for weight loss, triggering an "infodemic." While previous studies have characterized this landscape on Western platforms, the digital health ecosystem in China remains distinct. China is currently navigating a unique market shift driven by the June 2025 approval of the domestic dual agonist mazdutide, an impending 2026 patent cliff for semaglutide, and a specific market for counterfeit products. Objectives: To assess and compare the quality, reliability, and content completeness of health information regarding GLP-1 agonists on China's two dominant video platforms, Douyin (the Chinese version of TikTok) and Bilibili; to examine how platform architecture and regulatory context influence content reliability; and to contrast these findings with recent benchmarks from Western social media studies. Design: Cross-sectional observational study. Methods: A systematic search for "GLP1" was conducted on Douyin and Bilibili. Due to divergent algorithms, an asymmetric sampling strategy was used: all 106 videos returned by Douyin were screened, while the top 200 videos from Bilibili's default ranking were assessed. After applying exclusion criteria, 128 videos (56 Douyin, 72 Bilibili) were analyzed. Quality was evaluated using the modified DISCERN tool, Global Quality Score, and JAMA benchmarks. No human subjects were involved; therefore, ethical approval was not required. Results: Bilibili videos were significantly longer and demonstrated superior quality, scoring significantly higher than Douyin videos on both the DISCERN ( Conclusion: The Chinese digital landscape exhibits a quality tier on Bilibili that is absent in Western short-video counterparts. While Bilibili serves as a reliable "digital library," Douyin remains a high-risk environment for misinformation and counterfeit sales. As China approaches the 2026 patent cliff, regulatory bodies must address the specific threat of fraudulent "GLP-1" branding on illicit products. Trial registration: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.